Report of Foreign Issuer (6-k)
11 February 2016 - 6:50AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2016
Commission File No. 000-30082
MERUS LABS INTERNATIONAL INC.
(Translation of registrant's name into English)
100 Wellington St. West, Suite 2110 P.O. Box 151
Toronto, ON M5K 1H1
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or
Form 40-F
Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [ ]
SUBMITTED HEREWITH
Exhibits
|
|
99.1
|
News
Release Dated February 4, 2016 - Merus completes acquisition
of Elantan®, Isoket® and Deponit® rights from UCB and announces date of Q1 2016 earnings release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: February 4, 2016
MERUS LABS INTERNATIONAL INC.
/s/ Andrew Patient
_________________________________________
Andrew Patient
Chief Financial Officer
Exhibit 99.1
Merus completes acquisition of Elantan®,
Isoket® and Deponit® rights from UCB and announces date of Q1 2016 earnings release
TORONTO, Feb. 4, 2016 /CNW/ - Merus Labs
International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] announced today that it has completed
the previously announced acquisition of rights to Elantan®, Isoket® and Deponit® in Europe and select
other markets from UCB.
Merus also announced today that it will release
its fiscal earnings for the first quarter of fiscal 2016 after market close on Thursday, February 11, 2016. Merus will hold a conference
call at 8:30am ET on Friday, February 12, 2016 to discuss the results. Conference call details will be provided in the results
press release.
About Merus Labs
Merus Labs is a specialty pharmaceutical
company focused on acquiring established products. The Company leverages its expertise and commercial platform in Europe, Canada
and select other markets to deliver value.
Forward-Looking Statements
Certain statements contained in this press
release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation
Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements include statements relating to the
Company's future business and operating plans, the future pricing of the Company's products, the Company's ability to acquire future
products, the Company's ability to secure financing to complete acquisitions, and the Company's future results of operations. Such
statements involve assumptions relating to the Company's business, including government regulation of the pricing of the Company's
products, the competitive environment of the Company's products, the stability of foreign exchange rates and the availability of
prospective acquisition targets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors
that may cause the Company's actual results to be materially different from any future results expressed or implied by these statements,
including the guidance provided in this press release. Such factors include the following: general economic and business conditions,
changes in demand for Merus' products, changes in competition, the ability of Merus to integrate acquisitions or
complete future acquisitions, Merus' ability to complete any financing, interest rate fluctuations, currency exchange rate
fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. Investors should refer
to the Company's MD&A, Annual Information Form and Annual Report on 40-F for a more comprehensive discussion of the risks that
are material to the Company and its business. In light of these and other uncertainties, the forward-looking statements included
in this press release should not be regarded as a representation by Merus that Merus' plans, objectives and guidance
will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation
to update or revise the statements.
SOURCE Merus Labs International Inc.
%CIK: 0001031516
For further information: Phone: (416) 593-3725, Email: info@meruslabs.com
CO: Merus Labs International Inc.
CNW 18:03e 04-FEB-16